Related Experiment Video

Updated: Jun 3, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Antiangiogenic therapies: is VEGF-A inhibition alone enough?

Michael S Gordon1

  • 1Pinnacle Oncology Hematology, 9055 E Del Camino, Suite 100, Scottsdale, AZ 85258, USA. mgordon@azpoh.com

Expert Review of Anticancer Therapy
|March 23, 2011
PubMed

Insights

Newer antiangiogenic therapies targeting multiple vascular endothelial growth factor (VEGF) pathways may offer improved efficacy and overcome resistance. Panoramic inhibition of VEGF receptor-2 (VEGFR-2) shows promise for more effective cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Targeted therapies offer clinical efficacy but a need exists for antiangiogenic strategies with alternative mechanisms.
  • Resistance to current therapies necessitates novel approaches for improved patient outcomes.
  • Inhibiting multiple vascular endothelial growth factor (VEGF) targets may enhance efficacy and prevent resistance.

Purpose of the Study:

  • To review pivotal data on existing and developing VEGF/VEGFR inhibitors.
  • To explore the potential of broad-spectrum VEGFR-2 inhibition for enhanced antiangiogenic therapy.
  • To discuss strategies for circumventing resistance in antiangiogenic therapy.

Main Methods:

  • Review of pivotal data on VEGF/VEGFR inhibitors.
  • Focus on novel protein therapeutics like CT-322.
  • Analysis of panoramic inhibition of VEGFR-2.

Main Results:

  • Inhibition of VEGF-A, VEGF-C, and VEGF-D via broad-spectrum VEGFR-2 inhibitors may increase efficacy.
  • This approach may prevent or delay acquired resistance and metastatic spread.
  • Panoramic VEGFR-2 inhibition presents a potentially superior strategy for antiangiogenic therapy.

Conclusions:

  • Broad-spectrum VEGFR-2 inhibition offers a promising avenue for more effective antiangiogenic therapy.
  • Targeting multiple VEGF pathways can enhance efficacy and durability of response.
  • Novel agents and strategies are crucial for overcoming resistance in cancer treatment.

More Related Videos

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...